Figure 4.

Comparative effect of fractionated extracts from eDCM and eEtAc on glioma and astrocyte cell viability. Glioma cell lines were exposed to increasing concentrations of F1_DCM, F2_DCM, F3_DCM, F4_DCM, F3_EtAcand F4_EtAc fractions (A–F, respectively). In addition, primary astrocyte cultures (G) were exposed to the higher concentration of F1_DCM (10 μg/mL), F2_DCM (75 μg/mL), F3_DCM (10 μg/mL), F4_DCM (10 μg/mL), F3_EtAc (100 μg/mL) and F4_EtAc (100 μg/mL) fractions. Cell viability was determined by MTT test after 48 h of treatment. The values represent the mean ± SEM from at least three independent experiments performed in triplicate. Data were analyzed by ANOVA followed by post-hoc comparisons (Tukey test). ^{a, b, c} Significantly different from C6, U87MG, and U138MG control cells, respectively (P < 0.001).